Documentos relacionados

1. [Clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors].
2. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
3. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
4. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
5. CD4 T cells and toxicity from immune checkpoint blockade.
6. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
7. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
8. Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality.
9. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.
10. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.